Response Detection of Castrate-Resistant Prostate Cancer to Clinically Utilised and Novel Treatments by Monitoring Phospholipid Metabolism

Figure 1

Growth of LNCaP cells treated with paclitaxel (taxol) (a), flutamide (b), or Epi-1 (c) relative to untreated cells.

(a)

(b)

(c)